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Purpose/Objective: Curative (chemo-) radiation for head and neck 
cancer (HNC) may result in severe acute and late side effects, 
including tube feeding dependence. The purpose of this multicenter 
prospective cohort study was to develop a multivariate prediction 
model for tube feeding dependence 6 months (TUBEM6) after curative 
primary RT (radiotherapy), BioRT (radiotherapy + cetuximab) or CHRT 
(radiotherapy + chemotherapy) for head and neck cancer based on 
pre-treatment and treatment characteristics (including dose volume 
parameters) that can be used to select patients for radiotherapy 
treatment plan optimization.  
Materials and Methods: The study included 416 patients with HNC. In 
all patients, TUBEM6 was scored prospectively in a standardized follow-
up program. To design the prediction model, the penalized learning 
method LASSO was used, with TUBEM6 as the primary endpoint.  
Results: The incidence of TUBEM6 was 9.9% (41 out of 416 patients). 
Using the LASSO-parameter selection procedure, the multivariate 
model with the best model performance was selected, consisting of 
the following variables: male sex, advanced T-stage (T3-T4), 
moderate and severe weight loss at baseline, baseline CTCAE 
dysphagia-score, accelerated RT, CHRT, BioRT, the mean dose to the 
superior and inferior pharyngeal constrictor muscle (PCM), mean dose 
to the contralateral parotid gland and the mean dose to the 
cricopharyngeal muscle (CM) (see:Table). Model performance at 
internal validation in terms of area under the curve was 0.90 in 
double cross validation, while the prediction model scored excellent 
using other performance measures. Of the four dose-volume 
parameters, the mean dose to the PCM superior was most important.  
In the graph (see: Figure) an example of the predicted NTCP value for 
TUBEM6 as a function of the mean dose to the PCM superior is shown 
for a female patient with a T3-T4 tumor, with severe weight loss and 
dysphagia prior to the start of chemoradiotherapy.  
 
 
  
Conclusions: We developed a multivariate NTCP model for TUBEM6 
after definitive (chemo) radiation, which can be used to predict 
TUBEM6. The four dosimetric variables in this prediction model can be 
used to optimize RT treatment planning aiming at prevention of tube 
feeding dependence.  
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